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Abstract
Aims/hypothesis The prevalence of births worldwide
complicated by diabetes mellitus is increasing. In the
UK, for example, <25% of diabetic women have a non-
instrumental vaginal delivery. Strikingly, more than half
the Caesarean sections (CS) in these patients are non-
elective, but the reasons for this are not understood. We
have tested the hypothesis that poor myometrial con-
tractility as a consequence of the disease contributes to
this high CS rate.
Methods We compared spontaneous, high K depolarisation
and oxytocin-induced contractions from diabetic and
matched control patients having an elective CS. To
investigate the mechanism of any differences we measured
intracellular Ca, and performed western blotting and
compared the tissues histologically.
Results There was significantly decreased contraction
amplitude and duration in uteri from diabetic compared
with control patients, even when possible confounders
such as BMI were analysed. Reduced intracellular
calcium signals and expression of calcium entry chan-
nels were found in uteruses from diabetic patients,
which, along with a reduction in muscle content found
on histological examination, could explain the reduced
force. Myometrium from diabetic patients was respon-
sive to oxytocin, but still did not reach the levels found
in non-diabetic patients.
Conclusions/interpretations These are the first data inves-
tigating myometrium in diabetic patients and they support
the hypothesis that there is poorer contractility even in the
presence of oxytocin. The underlying mechanism is related
to reduced Ca channel expression and intracellular calcium
signals and a decrease in muscle mass. We conclude that
these factors significantly contribute to the increased
emergency CS rate in diabetic patients.
Keywords Calcium.Diabetes.Force.Muscle histology.
Myometrium.Oxytocin.Smooth muscle.Translational
medicine
Abbreviations
ANCOVA Analysis of co-variance
au Arbitrary units
CEMACH Confidential Enquiry into Maternal and Child
Health
CS Caesarean section
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GTT Glucose tolerance test
H&E Haematoxylin and eosin
S. Al-Qahtani and A. Heath contributed equally to this study.
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-011-2371-6) contains peer-reviewed but unedited
supplementary material, which is available to authorised users.
S. Al-Qahtani:A. Heath:R. Floyd: T. Burdyga: S. Wray (*)
Department of Molecular and Cellular Physiology,
Institute of Translational Medicine, University of Liverpool,
Crown Street,
Liverpool L69 3BX, UK
e-mail: s.wray@liv.ac.uk
S. Quenby:F. Dawood
Liverpool Women’s Hospital, University of Liverpool,
Liverpool, UK
S. Al-Qahtani
Department of Physiology, Medical College, Jazan University,
Jazan, Kingdom of Saudi Arabia
Present Address:
S. Quenby
Clinical Sciences Research Institute, University of Warwick,
Coventry, UK
Diabetologia (2012) 55:489–498
DOI 10.1007/s00125-011-2371-6Introduction
Worldwide, diabetes in pregnancy is associated with signifi-
cant fetal and maternal morbidity and mortality. The preva-
lence of births complicated by pre-existing diabetes has
increased by 50% in under a decade [1]. There is a consensus
among researchers that the Caesarean section (CS) rate is
higher in women with diabetes [2–4], with the Confidential
Enquiry into Maternal and Child Health (CEMACH)
reporting a rate of 67.4% [5]. The OR for risk of emergency
CS in pregnancy complicated by a diabetic pregnancy is 3–4
[2, 6]. CEMACH reported that 56% of CS were emergency
operations not elective ones. CS in women with diabetes in
pregnancy is associated with a 2.5-fold increased risk of
wound infection [7], and an increased risk of thrombosis and
post-partum haemorrhage [4]. Despite the significant atten-
dant morbidity associated with CS in diabetic pregnancies,
the high CS rate in diabetic pregnancies is not understood.
Some authors suggest that the increased CS rate is due to
the confounding factor of obesity [8]; however, other
analyses have found diabetes mellitus to be an independent
risk for CS [2, 9, 10]. Other putative factors are macro-
somia, increased fetal distress and poor myometrial activity.
Although macrosomia has been reported as a risk factor for
CS in women with diabetes [2, 10], recent work has found
that a reduction in macrosomia does not result in a
concomitant reduction in CS rate [11–13]. Fetal distress is
cited as a reason for emergency CS in diabetes [6], and
fetuses of diabetic mothers are more vulnerable at term,
with increased stillbirth rate [3, 4, 6, 14].
However, although fetal distress, macrosomia and obesity
contribute to the increased emergency CS rate in diabetic
pregnancies, prolonged labour and failed induction of labour
accounted for 51% of emergency CS [6]. Therefore, poor
myometrial contractility may be important. Further evidence
to implicate poor myometrial contractility is that post-partum
haemorrhage is six times more common in diabetic women
[4]. Post-partum haemorrhage may be attributed to altered
oxytocin responsiveness; however, clinical conditions linked
to altered smooth muscle function with diabetes in other
tissues include hypertension, gastric paresis, constipation,
urine retention and vas deferens dysfunction. In vitro studies
have found tissue-specific alterations in contractility [15–20],
thus it is difficult to predict what the effects of diabetes
mellitus may be on uterine contractions. There are few data
concerning the effect of diabetes in the myometrium of any
species and none on Ca signalling [21–24]. In the only study
on human myometrium, which involved seven women who
developed gestational diabetes, an increased response to
endothelin-1 was reported [25], but no clinical information
was presented.
Thus, the purpose of our study was to elucidate whether
the contractility of human myometrium is impaired in
women with pregnancies complicated by diabetes and to
explore the underlying mechanisms. These data in turn will
shed light on the question of whether their high CS rate
may be partly explained by poor contractility.
Methods
Patient details Following ethics approval and informed
consent, lower segment biopsies were taken at the time of
elective CS from 40 patients with diabetes and 68 without.
Hospital protocol is to perform elective CS at 39 weeks
gestation for non-diabetic patients and 38 weeks for
diabetic patients. Clinical and demographic data are
presented in Tables 1, 2, 3. None of the patients in this
study were in labour or had a multiple pregnancy.
All non-diabetic patients were screened initially with a
detailed medical and obstetric history. If there is any factor in
the history, for example previous big babies >4.5 kg, family
history of diabetes, ethnicity (Asian), then patients automat-
ically undergo a glucose tolerance test (GTT) between 24 and
28 weeks. Furthermore, if glycosuria is >2+ glucose detected
in urine dipstix checked every 2 weeks, then this also prompts
testing for GTT. Age >35 years without any risk factors does
not lead to automatic GTT screening. In our unit we employ
the WHO 75 g glucose load administered to fasting patients
and then check glucose readings at 1 and 2 h. By these criteria
none of the patients in our control group had detectable
gestational diabetes mellitus. This was a specific exclusion
criterion. Other exclusion criteria were pre-eclampsia and
medication likely to affect contractility.
Force and calcium measurements Tissue preparation and
measurement of calciumwere asdescribedelsewhere [26, 27].
In brief, dissected muscle strips (1×3 mm) were incubated in
the Ca
2+-sensitive indicator Indo-1 (12.5 μmol/l), for 2–3ha t
room temperature. The strips were rinsed in physiological
saline (see below) and then, with one end attached to a force
transducer, mounted horizontally in a small (500 μl) bath for
simultaneous measurement of force and Ca signalling.
Tissues were superfused (3 ml/min) with physiological saline
at 35°C. For Ca
2+ measurement the tissues were excited at
340 nm and the Indo-1 fluorescence emitted at 400 and
500 nm was recorded. The ratio of these signals (F400/500)
provides a measure of [Ca] [28]. Previous studies have shown
that lower segment biopsies are a good model for studying
human myometrial contractility [29].
Solutions Physiological saline with composition (mmol/l)
154 NaCl, 5.4 KCl, 1.2 MgSO4, 8 glucose, 2 CaCl2,1 1
Hepes; pH 7.4. In some experiments oxytocin (10 nmol/l)
or the Ca
2+ channel agonist BAY K-8644 (1 μmol/l) were
added to the perfusate.
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taneous contractions were exposed to 40 mmol/l KCl solution
(K
+ substituted for Na in the physiological saline) for 2 min
to obtain a measure of maximal activity, which could also be
used to standardise between preparations. After stable
contractions were established, a control period of 60 min
was obtained before the physiological solution was altered.
The frequency of contractions was obtained over this control
period. The last three contractions of this control period were
used to determine average peak amplitude and duration at
half-height. The integral of force (area under the curve, in
arbitrary units [au]) was obtained over the last 20 min of the
control period. Only one result was obtained from each
patient, thus n is the number of patients. Data were obtained
and analysed in a blinded fashion.
Histology Paraffin-embedded 5 μms e c t i o n sw e r em a d ef r o m
ten control and diabetic myometria, and stained with both
haematoxylin and eosin (H&E) to allow measurement of
muscle bundles and uterine histology. Sections were also
stained with Masson’s Trichrome to allow measurement of
collagen deposition compared with muscle. Samples were
viewed at ×40 magnification by two independent observers
blinded to the origin of the samples. Muscle bundles were
assessed in semi-quantitative fashion in terms of muscle
bundlesize,organisationand separation.Todetermine muscle
percentage and collagen deposition, images were captured
using Eclipsenet software (Nikon, Nikon UK, Kingston upon
Thames, UK) from ten randomly selected regions per sample,
imported into ImageJ freeware (NIH, Bethsheda, MD, USA)
and analysed using colour-based thresholding [30].
Western blotting and immunohistochemistry Proteins were
extracted, quantified and separated by SDS-PAGE and
transferred to polyvinylidene difluoride (PVDF) membranes
using previously described methods [31]. Membranes were
probed overnight with agitation at 4°C with primary
antibodies as follows: rabbit polyclonal L-type calcium
channel α1C 1:200 (Alomone) or mouse monoclonal
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 1:400
(AbCam) diluted in 5% non-fat dried milk in TBS/0.1%
(vol./vol.) Tween 20 (TBST) or 5% protease-free bovine
serum albumin in TBST respectively. Immunoreactive sites
were revealed using goat anti-rabbit or goat anti-mouse IgG
conjugated to horseradish peroxidase and SuperSignal West
Pico substrate (Pierce-Perbio Science, Cramlington, UK).
Tissue microarrays containing formalin-fixed paraffin-
embedded samples of ten diabetic and ten non-diabetic
myometrial tissues were processed as described in detail
elsewhere [32]. Microarrays also contained rat heart and
Table 1 Patient details: type 1 diabetes mellitus (n=18)
Age
(years)
BMI
(kg/m
2)
Diabetic complications HbA1c (range) Type of insulin Parity Gestational
age (weeks)
Birthweight
(kg)
Caesarean indication
% mmol/mol
40 31.6 None 6.1–6.2 43–44 Humulin; humalog 1 38 3.69 Previous CS
40 22.3 None 5.9–6.4 41–46 Humalog; lantus 1 38 3.49 Maternal request
26 28.9 Retinopathy 6.4–6.6 46–49 CSII 0 35+2 2.18 Maternal request
24 30.1 Microalbuminuria 7.9–8.1 63–65 Novorapid, glargine
a 0 38 3.34 Previous CS
36 24.6 None 6.0–7.0 42–53 Novorapid, lantus 1 37+4 4.5 Diabetes
CSII
36 22.4 Previous nephropathy 6.5–6.8 48–51 CSII 1 36+4 4.42 Maternal reason
27 41.9 None 7.9–9.7 63–83 Humalog; lantus 2 35+3 4.48 Diabetes
39 30 Retinopathy 6.4–8.2 46–66 Humalog; humulin 0 34+0 2.58 Previous CS/
maternal request
44 31.2 Vascular 6.3 45 Insulin 3 36+4 2.72 Maternal reason
29 22.3 None 5.7–6.3 39–45 Insulin 1 38 3.26 Diabetes
28 43 Nephropathy 7.1–7.5 54–59 Novorapid, lantus 3 35+2 4.37 Diabetes
34 43.8 None 6.7 50 Insulin 1 37+1 4.31 Previous CS
37 22.6 Retinopathy 6 42 Novorapid, lantus 3 32+6 2.48 Maternal reason
38 25.2 Hypertension 6.5 48 Novorapid, lantus 3 36+3 4.115 Previous CS
27 24.2 None 5.9 41 CSII 3 33+5 2.46 Breech
41 46.2 Hypertension 6.1 43 Novorapid, lantus 1 37.5 3.29 Previous CS
36 24.8 Retinopathy and
nephropathy
5 31 Novorapid, lantus 0 37 3.27 Diabetes
40 36.5 None 5.5–6.0 37–42 Novorapid 2 38 3.75 Previous CS
aInsulin glargine (A21Gly,B31Arg,B32Arg human insulin)
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chemistry was performed as described previously [31]a n d
[33] using rabbit polyclonal L-type calcium channel α1C
(Alomone) antibody diluted 1:100 in TBST/1% protease-free
bovine serum albumin applied overnight at 4°C. Control
experiments were performed by incubating slides with non-
immune rabbit serum or by omitting primary antibody, or by
peptide competition of 1 μgp e p t i d ep e r1μga n t i b o d y .
Image capture of immunostained sections was performed
using an Olympus BX51 microscope with a PL-A662
firewire camera (PixeLINK, Ottawa, ON, Canada) using a
×20 objective. Western blot signal quantification was carried
out using ImageJ for Windows and the relative band
intensities corresponding to L-type calcium channel expres-
sion are expressed as a percentage of the GAPDH internal
control for each sample. Blots from three repeat experiments
were scanned in 128 shades of grey and thresholding was
used to segment blots into objects of interest.
Chemicals were from Sigma, Dorset, UK unless indicated
otherwise.
Table 2 Gestational diabetes mellitus (n=22)
Age
(years)
BMI
(kg/m
2)
HbA1c (range) Type of insulin Parity Gestational
age (weeks)
Birthweight
(kg)
Caesarean
indication
% mmol/mol
26 35.4 5.4–7.0 36–53 Insulin: novomix 1 38 3.71 Previous CS
29 42.5 6.9–7.2 52–55 Metformin and insulin:novomix 1 38+1 4.16 Previous CS
30 40.7 5.1–5.6 32–38 Metformin and insulin:lantus 1 38 3.2 Previous CS
33 26.5 5.3–5.6 34–38 Diet only 1 38 3.57 Previous CS
38 28.9 5.1–5.3 32–34 Diet only 1 39 3.57 Previous CS
37 35.6 5.6–5.7 38–39 Diet only 1 38 3.74 Previous CS
33 29.8 4.4–5.8 25–40 Diet only 2 37+6 4.83
38 27.8 5.4–7.0 36–53 Diet only 2 36+5 2.78 Previous CS
31 24 5.1 32 Insulin: lantus 1 38+6 3.03 Previous CS
38 38 7.0–9.3 53–78 Insulins: novorapid and lantus 1 38+1 4.76 Previous CS
36 31.5 7.4 57 Metformin 1 38+3 3.9 Previous CS
35 33.7 4.1–6.2 21–44 Insulins: novorapid and lantus 2 38+1 3.3 Diabetes
35 19.4 4.2–6.5 22–48 Diet only 3 38+2 3.25 Diabetes
29 24.8 5.8–6.0 43–42 Insulins: novarapid and lantus 0 38 3.98 Previous CS
30 21.5 4.5–6.8 26–51 Insulin: novorapid 1 37+5 4.15 Breech
32 28.1 6.4 46 Diet only 1 37+1 4.31 Previous CS
27 50.1 4.7 28 Diet only 1 37+5 4.11 Previous CS
36 23.8 6.3 45 Diet only 1 38+3 2.68 Breech
29 53.1 6.7 50 Diet only 1 36 3.23 Hypertension
27 50.7 8.5 69 Novorapid, lantus 1 37+4 3.23 Previous CS
37 32.4 5.7–5.9 39–41 Novorapid, lantus 1 37+3 5.05 Previous CS
32 26.2 5.5 37 Novorapid 2 38 3.8 Previous CS
Table 3 Demographics of diabetic and non-diabetic patient groups
Variable Type 1 diabetes mellitus Gestational diabetes mellitus Non-diabetic controls
Age (years) 36 (28–39) 33 (30–37) 33 (24–44)
BMI (kg/m
2) 29.5 (24–32) 29 (26–35) 27 (19–45)
Gestational age (weeks) 37 (35–37) 38 (37–38) 39 (37–40)
Birthweight (kg) 3.42 (2.72–4.30) 3.73 (3.20–4.20) 3.48 (2.69–4.48)
Data are median (interquartile range) from the patient groups
All data in all groups were from women having an elective Caesarean section, i.e. they were not in labour. Elective section before 37 weeks in
non-diabetic patients was due to placenta praevia, and before 38 weeks was due to rhesus disease, maternal request, placenta praevia or unstable
See ESM Table 1 for full control patient data
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biopsies and only one set of data was obtained from
each biopsy. Experimental data were analysed using
Mann–Whitney U, Wilcoxon, analysis of co-variance
(ANCOVA) or Student’s t test with significance taken at
p<0.05. Results are expressed as median (first and third
quartile) or mean±SEM.
Results
Patients There were no significant differences in maternal
age, BMI and birthweight between type 1 diabetic (n=18),
gestational diabetic (n=22) and non-diabetic patients (n=68;
Tables 1, 2, 3, and electronic supplementary material [ESM]
Table 1). Type 1 diabetic patients were delivered typically at
38 weeks in order to avoid unheralded stillbirth, or earlier if
there was fetal compromise or deterioration in maternal
health. However, the mean gestational age of delivery for the
type 1 diabetic patient remains comparable with both the
gestational diabetic group and the control group, as shown.
Spontaneous contractility There were significant differ-
ences in the contractions between samples from diabetic
and non-diabetic patients; the contractions were smaller and
shorter-lasting in diabetic patients (Fig. 1c, Table 4). When
normalised to high K contractions (100%) these variables,
were also significantly lower in the diabetic patients, 65%
(55, 82%) compared with 80% (61, 90%) in non-diabetic
controls; see also Fig. 1c. The significant decreases in
contractility resulted in the AUC also being significantly
less in diabetic patients, 2.1 (1.1, 3.5) au, compared with
non-diabetic controls, 8.7 (4.0, 14.5) au. ANCOVA was
used to determine the effects of possible confounders: age,
BMI, birthweight and gestational age. The decreased
contractility in myometrium from diabetic patients
remained significant (p<0.05).
The effect of oxytocin Oxytocin was added to the perfusate
after spontaneous contractions had been established. In
non-diabetic patients (n=7), it produced a marked increase
in uterine contractility and underlying Ca
2+ signals
(Fig. 1b). Thus the amplitude and AUC of both contractions
and Ca
2+ showed significant increases; when compared
with spontaneous contractions (100%), the mean amplitude
and contraction AUC were 184±15% and 337±46% au,
respectively. In diabetic patients (n=6), oxytocin also
produced a significant increase in both, which were not
significantly different from that found in control group,
219±26% and 332±83% respectively (Fig. 1d). However, in
the diabetic samples contractility, even when stimulated with
oxytocin, remained significantly reduced when compared
with oxytocin stimulation in non-diabetic patients.
High K solution As a significant decrease in Ca
2+ transient
amplitude and duration was found in uteruses from diabetic
patients, we investigated if this was due to a lack of
activation of the L-type Ca
2+ channels by using high K
+
depolarisation to open calcium channels.
Fig. 1 Spontaneous, oxytocin and high K-induced activity. Spontane-
ous and oxytocin-induced activity. a and c Simultaneous measurements
of force and Ca (Indo-1) in myometrium from non-diabetic (a)a n d
diabetic patients (c) during spontaneous activity. Typical records from
40 diabetic and 68 non-diabetic patients. Effects of 10 nmol/l oxytocin
(b and d), typical of at least five other records for both groups. e
Comparison of the effects of 40 mmol/l K stimulation after a
spontaneous contraction in non-diabetic and diabetic myometrium,
typical of 13 others. f and g Representative Indo-1 records showing the
Ca signals in response to spontaneous (f) and high K stimulation (g)i n
samples from non-diabetic and diabetic patients. In this and subsequent
samples all data were obtained on myometrium from elective CS
biopsies at 35°C and superfused physiological solution containing
8 mmol/l glucose
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40 mmol/l K
+ produced a large increase in force, which
plateaus and then declines. A similar response pattern
occurred in both types of biopsy but the amplitude was
significantly greater in non-diabetic 3.0 mN (1.3, 4.5)
compared with diabetic samples 1.5 (0.8, 3.0). There were
also significant differences in the duration and AUC (Table 4).
Ca channels Immunohistochemical studies revealed the α1C
subunit in myocyte membranes (Fig. 2a, non-diabetic
myometrium n=10, diabetic myometrium, n=10).
Figure 2a (bottom) shows controls and negative control
with antibody-peptide adsorption. Relative abundance of
L-type calcium channel immunoreactivity was reduced
in diabetic samples compared with age-matched myometrial
samples from non-diabetic patients. Western blotting revealed
a ∼220 kDa band, the predicted molecular weight of L-type
calciumchannels(n=9 non-diabetic and ten diabetic patients,
Fig. 2b). Analysis of signal intensity revealed a small but
significant decrease in L-type calcium channel expression in
diabetic (63.64±3.694%) compared with non-diabetic myo-
metrium (76.85±3.911%) when expressed as a percentage of
GAPDH internal control expression.
As can be seen in Figs 1 and 2, the changes in
contractility in both non-diabetic and diabetic myometrium,
whether occurring spontaneously or in response to oxytocin
or high K
+ solutions, were a reflection of the changes in
intracellular [Ca
2+], as recorded by Indo-1 fluorescence.
Table 2 gives the time to peak amplitude, duration at half-
height, relaxation time and AUC of the Ca
2+ transients. All
apart from time to peak were significantly reduced in the
diabetic samples. To further investigate the mechanism
underlying the transient fall in Ca
2+ in diabetic samples, we
used the agonist BAY K-8644, which increases the open
probability of L-type Ca
2+ channels. Figure 2c shows the
effect of the L-type Ca
2+ channel opener Bay K8644
(1 μmol/l). Application of BAY K-8644 produced a large
stimulation of Ca
2+ entry and augmentation of force in both
diabetic (n=5) and non-diabetic (n=5) samples. Baseline
Ca
2+ and force were also elevated. As can be seen in
Fig. 2c, however, diabetic samples showed significantly
smaller increments in AUC for both force and Ca
2+,
compared with control values of 100%: in diabetic
patients their increases were 194±36% and 124±20%,
respectively, whereas in non-diabetic patients these values
were 353±48% and 224±36%.
Histology Light microscopic examination of H&E-stained
myometrial sections from ten diabetic and ten non-diabetic
patients were examined. There were no differences in
myometrial appearance from diabetic samples; muscle bundle
size, organisation and separation were all normal (Fig. 2d).
The percentage muscle for each section was calculated and
the overall average taken for both groups. There was a small
but significant (p<0.001) reduction in the muscle content of
the diabetic compared with the non-diabetic sections (79.9±
1.1% vs 86.7±1.2%) respectively. Masson’s Trichrome
stained sections were used to investigate if this difference
in muscle content was due to alterations in collagen
deposition. There was a small but significant (p<0.02)
reduction in the muscle content of the diabetic compared
with the non-diabetic sections (44.8±2.2% vs 54.1±1.3%)
respectively (Fig. 2e). Analysis of the collagen deposition
showed a non-significant change in the collagen deposition
in the diabetic group (22.1±1.9% vs 26.2±2.9%).
Effect of diet versus insulin diabetic control The majority
of patients were using insulin to control their blood glucose
Table 4 Variables of contraction and Ca transients in diabetic and non-diabetic patients
Variable Spontaneous contractions High K contraction
Contractions Ca signals
Non-diabetic
(n=68)
Diabetic
(n=40)
Non-diabetic
(n=15)
Diabetic (n=9) Non-diabetic
(n=14)
Diabetic
(n=14)
Frequency (contraction/h) 8 (6, 12) 7 (5, 13) –– – –
Amplitude (mN) 2.4 (1.2, 4.5) 1.5 (0.9, 2.6)* 0.7 (0.3, 1.0) 0.2 (0.1, 0.5) 3 (1.3, 4.5) 1.5 (0.8, 3.0)*
Duration (min) 1.7 (1.1, 2.5) 0.9 (0.6, 1.3)* 2.0 (1.2, 3.3) 1.0 (0.8,1.7)* 2.1 (1.3, 3.6) 1.2 (0.8, 1.8)*
AUC (au) 8.7 (4.0, 14.5) 2.1 (1.1, 3.5)* 4.4 (2.0, 7.2) 1.1 (0.6, 1.7)* 5.4 (3.5, 16.4) 2.8 (1.3, 3.5)*
Relaxation rate (min) N/A N/A 5.0 (4.7, 9.1) 2.4 (0.7, 4.5)* N/A N/A
Median data with first and third quartiles in parenthesis
AUC for spontaneous contractions obtained over the last 20 min of the control period, whereas for KCl it was obtained from one contraction
developed in response to 2 min exposure to high KCl
*p<0.05
N/A, not available
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control alone. We therefore analysed them separately
and compared the data to those for patients taking
insulin. There were no significant differences between
groups (data not shown).
Discussion
By studying a large number of uterine biopsies from
pregnant diabetic patients we have found that when
compared with matched non-diabetic patients, contractility
is significantly reduced. Analysis of the diabetic patients
showed that these findings held even when insulin-treated
were compared with diet-controlled gestational diabetic
patients. Contractility was poorer in the diabetic samples
whether arising spontaneously, with oxytocin or high K
+;
calcium channel expression and signalling were reduced
and are likely to account for the reduction in contractility.
The reductions in Ca signals are consistent with the reduced
Ca
2+ channel expression and function in myometria from
diabetic patients. The small but significant decrease in
myometrial mass will also contribute to the decreased
contractility. Our data suggest that in labour, myometrial
activity will be poorer in diabetic patients and will lead to
an increase risk of CS even when controlling for other
factors such as obesity and hypertension.
Effects on contractions There are few studies investigating
myometrial contractility in diabetes with which to compare
our data. Force in isolated uteruses from diabetic rats was
decreased compared with control rats [22], consistent with
our data on human myometrium. An earlier report on human
myometrium from diabetic patients noted that the stability of
contractions, as measured by their decrement within 1 h, was
reduced in diabetic patients, that is, force was reduced faster
[25]. However, although we found the amplitude and
duration of contractions to be reduced in diabetic patients,
this activity was well maintained for several hours. Unfor-
tunately, Kaya et al. [25] did not compare contraction
amplitude or any other parameters of contraction. Thus, our
study is the first to document the changes in contractility in
human myometria from diabetic patients, and it reveals that
the spontaneous contractions and their accompanying Ca
transients were significantly lower in diabetic patients
compared with non-diabetic patients. The amplitude and
duration were significantly decreased, so much so that the
AUC was only half that of the non-diabetic patients.
No previous work has investigated the effect of oxytocin
on human diabetic myometrium. A previous study on
myometria from diabetic rats reported that oxytocin
stimulation was similar to that in control rats [22], whereas
McMurtrie et al. [21] found maximal responses reduced.
We found that oxytocin increased myometrial force and
calcium transients in non-diabetic and diabetic patients
Fig. 2 Uterine histology and Ca
channels. a Tissue distribution
of L-type calcium channels. Im-
munohistochemical localisation
of L-type calcium channels in
non-diabetic and diabetic
myometrium with positive and
negative controls underneath.
Scale bar, 50 μm. b Quantifica-
tion of L-type calcium channel
expression. Densitometric
western blot quantification of
L-type calcium channels in
non-diabetic and diabetic
patients. c Effect of Bay K-8644
stimulation. Simultaneous
measurements of force and Ca
(Indo-1) in myometrium from
non-diabetic and diabetic
patients during spontaneous
activity and with application of
1 μmol/l of the Ca channel
agonist, Bay K-8644. d and
e Myometrial histology. d H&E.
e Masson’s Trichrome-stained
uterine sections from non-
diabetic and diabetic patients.
Scale bar, 50 μm. Significant
difference, *p<0.05
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respond to oxytocin, making it unlikely that oxytocin
receptors have been downregulated or that the signalling
pathways elicited by it are impaired. In other smooth
muscles mainly studied in diabetic animals, both increased
and decreased agonist responses are reported (e.g. [34–36])
and no consistent mechanism has been identified.
Our data with high K
+ stimulation showed a significant
decrease in amplitude of force and Ca rise in diabetic
samples. There is no consistency in the reported effects of
high K+ on other smooth muscle preparations from diabetic
tissues, with similar findings to ours reported by some [36–
38], but no change or increase by others [20, 39]. Our data
are consistent with those of Wang et al. [40], who also
found decreased L-type Ca
2+ current density discussed
below, but our data could also be due to decreased channel
expression and altered channel kinetics.
Histology The differences in force output in the uterine
biopsies from patients with diabetic pregnancy may be due
to structural changes. No obvious differences in cellular
abundance or orientation were seen at the light microscopic
level, but there was a difference in the amount of muscle
present. There have been no other histological studies of
diabetic human myometrium and only one electron micro-
scopic study performed in rats [21]. These authors saw no
differences in nuclei or mitochondria between streptozotocin-
treated and control rats but noted, with no quantification or
elaboration, that the number and cellular orientation of
myofilaments in euglycaemic animals ‘appeared different’.
Ca signalling Myometrial contractility is dependent on
calcium influx via voltage-gated channels, and hence on
membrane potential [41, 42]. Changes in myosin phos-
phorylation and Ca sensitivity with diabetes have been
reported in a study of bladder smooth muscle, but changes
in Ca sensitisation are not a prominent feature of myome-
trium [43]. We found that calcium transient amplitude and
duration are less in diabetic compared with non-diabetic
samples. Therefore, a defect in channel activation, function
or expression may occur as a consequence of the diabetic
environment. Despite the large number of studies from
diabetic animals reporting impaired contractility, few
studies have investigated the underlying mechanisms or
measured intracellular Ca
2+.
Studies of resting membrane potential show no significant
changes with diabetes [36, 44, 45], suggesting that K
+
channel activity is unaltered. Reduction in release of Ca
2+
from the sarcoplasmic reticulum, Ca
2+ sparks, and activators
of Ca-activated K channel (BK) channels was reported in
coronary micro-vessels with diabetes in pigs [46]. However,
such mechanisms are unlikely to play a role in the uterus as
Ca
2+ sparks are not present [47]. Consistent with no change
in membrane potential, we found no difference in the resting
Indo-1 ratios, suggesting no change in resting [Ca], in
agreement with data on bladder muscle cells [48].
Stimulation of diabetic uterine tissue with oxytocin and
high K produced large rises in Ca, indicating that these
pathways to Ca
2+ mobilisation were functional. Thus, our
data do not support a role for alteration in the initiation of
Ca
2+ signalling with diabetes mellitus but rather point to
changes in the expression or regulation of L-type Ca
2+
channels, perhaps as a consequence of glycosylation of
residues. There is evidence to support this in our data and
other studies. Wang et al. [40] found a decrease in current
density, but no change in cell capacitance, studying rat tail
arteries. In cardiac muscles, diabetes is associated with
impairment of contraction, and reduced intracellular Ca [49,
50], caused by a reduction in the Ca
2+ current. This, in turn,
has been attributed to a decrease in Ca channel function or
expression [49, 50]. Wang et al. also found a stimulatory
effect of BAY K-8644 in diabetic preparations, as we did in
the uterus, suggesting that the number of Ca
2+ channels
may be reduced, as it could improve Ca
2+ signalling in
diabetic myometrium but not restore signals to the level
found in non-diabetic samples. A similar argument can be
made to explain our high K
+ data.
In summary, our data point to both histological and
cellular changes occurring in diabetic patients that com-
pound to reduce contractility, and Ca
2+ signalling. What the
mechanistic trigger for this is remains to be investigated in
further studies. In particular, the role of changes in insulin
receptors and protein glycosylation should be examined.
The impact of diabetes on labour outcome Studies world-
wide have shown a much higher CS rate in diabetic compared
with non-diabetic patients [2–4]. Although fetal distress,
macrosomia and obesity may contribute to this increased
emergency CS rate, prolonged labour and failed induction of
labour accounted for 51% of emergency CS [6]. Therefore,
poor myometrial contractility has been suggested as an
important factor in diabetic pregnancies, and our data support
this conclusion. Before discussing the implications further,
we will first discuss some aspects of our patient data.
Our data are based on 40 diabetic myometrial biopsies.
With any study of human disease there will be confounding
factors and complications, and in diabetes factors such as
obesity can complicate interpretation. However, as shown,
there were no significant differences in median age, parity,
BMI or birthweight between our groups and our data
remained significant when confounders were analysed. We
also found that the difference held when method of control
of glucose was examined; contraction was reduced in both
the insulin patients and those exercising dietary control.
Thus, we conclude that it is the diabetic environment that is
responsible for the reductions in force we have found.
496 Diabetologia (2012) 55:489–498This impaired contractility, if translated in vivo
would lead to poor labour contractions and failure to
progress. This, in turn, would be an indication for CS
and thus our findings help explain the increased rate of
CS in diabetic patients. As we have shown, this
impairment persists even with oxytocin stimulation and
may help explain why progress in labour may remain
poor in diabetic patients, even when oxytocin is
administered. Diabetic patients also experience a higher
rate of failed labour induction than non-diabetic patients
[6]. Although the reasons for this are unknown, we
suggest that the poorer contractility in diabetic patients
will play a role, although other endocrinological changes
such as oestrogen levels cannot be excluded. Nationally
and internationally, clinical management of diabetic
labours (induction of labour or oxytocin augmentation) is
non-specific, that is exactly the same as in non-diabetic
patients. Dosages of oxytocin are only altered depending
on parity or a history of a previous Caesarean section.
Pursuant to our extensive laboratory data, we suggest that
all diabetic labours should be considered a unique entity
and require a different approach compared with non-
diabetic patients. We hypothesise that a higher dosage
increment or a longer duration of oxytocin may be
required in diabetic labours to counteract the inherent
poor uterine contractility, although any adverse outcomes
of using higher dosages of oxytocin would need to be
considered. We are aware of an ongoing study (HOLDS,
www.holds.bham.ac.uk) that is examining the role of
higher doses of oxytocin for augmentation in non-
diabetic patients. Such augmentation measures may reduce
the number of failed inductions as well as the number of
women having poor progress in labour.
In conclusion, our data give insight into the effects of
diabetes on human myometrium. This is the first study to
investigate contractile activity—including that induced by
oxytocin. Our findings that, irrespective of the mechanism
generating contractions, there is a deficit in force compared
with non-diabetic patients adds to the clinical data suggest-
ing that poor myometrial contractility may be an important
factor in diabetic pregnancies.
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